Valneva SE Market Cap ($543.87 Million)
Market Cap & Net Worth: Valneva SE (VLA)
Valneva SE market cap. Valneva SE (PA:VLA) has a market capitalization of $543.87 Million (€465.20 Million) as of November 1, 2026. Listed on the PA stock exchange, this France-based company holds position #11408 globally and #178 in its home market, demonstrating a 2.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Valneva SE's stock price €2.45 by its total outstanding shares 189646915 (189.65 Million). Also see VLA cash generation efficiency for how efficiently the company converts equity into cash flow.
Valneva SE Market Cap History (2015–2026)
Valneva SE market cap history from 2015 to 2026. Data shows change from $842.53 Million to $543.87 Million (-2.57% CAGR). Check Valneva SE stock quote for real-time trading data and today's change.
Index Memberships
Valneva SE is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid 60
CACMD
|
$186.01 Billion | 0.29% | #47 of 55 |
|
CAC Mid & Small
CACMS
|
$221.72 Billion | 0.25% | #65 of 119 |
|
CAC All-Tradable
CACT
|
$2.79 Trillion | 0.02% | #125 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.79 Trillion | 0.02% | #125 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.79 Trillion | 0.02% | #125 of 179 |
|
CAC PME
CAPME
|
$39.20 Billion | 1.39% | #13 of 34 |
|
CAC Health Care
FRHC
|
$262.86 Billion | 0.21% | #16 of 36 |
Weight: Valneva SE's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Valneva SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Valneva SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VLA shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.72x
Valneva SE's market cap is 4.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $685.11 Million | $94.06 Million | -$49.18 Million | 7.28x | N/A |
| 2017 | $614.16 Million | $105.29 Million | -$11.48 Million | 5.83x | N/A |
| 2018 | $702.84 Million | $113.03 Million | $3.26 Million | 6.22x | 215.33x |
| 2019 | $569.81 Million | $126.20 Million | -$1.74 Million | 4.52x | N/A |
| 2020 | $1.72 Billion | $110.32 Million | -$64.39 Million | 15.58x | N/A |
| 2021 | $5.43 Billion | $348.08 Million | -$73.42 Million | 15.61x | N/A |
| 2022 | $1.38 Billion | $361.30 Million | -$143.28 Million | 3.82x | N/A |
| 2023 | $1.05 Billion | $153.71 Million | -$101.43 Million | 6.81x | N/A |
| 2024 | $479.35 Million | $169.58 Million | -$12.25 Million | 2.83x | N/A |
| 2025 | $824.34 Million | $174.66 Million | -$115.19 Million | 4.72x | N/A |
Competitor Companies of VLA by Market Capitalization
Companies near Valneva SE in the global market cap rankings as of November 1, 2026. Also see Valneva SE total assets for a full breakdown of the balance sheet.
Key companies related to Valneva SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Valneva SE (2015–2026)
Market capitalization of Valneva SE from 2015 to today. Between 2015 and today, Valneva SE's market cap moved from $842.53 Million to $ 543.87 Million, with a yearly change of -2.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €543.87 Million | -34.02% |
| 2025 | €824.34 Million | +71.97% |
| 2024 | €479.35 Million | -54.19% |
| 2023 | €1.05 Billion | -24.16% |
| 2022 | €1.38 Billion | -74.60% |
| 2021 | €5.43 Billion | +216.13% |
| 2020 | €1.72 Billion | +201.56% |
| 2019 | €569.81 Million | -18.93% |
| 2018 | €702.84 Million | +14.44% |
| 2017 | €614.16 Million | -10.36% |
| 2016 | €685.11 Million | -18.68% |
| 2015 | €842.53 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Valneva SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $543.87 Million USD |
| MoneyControl | $543.87 Million USD |
| MarketWatch | $543.87 Million USD |
| marketcap.company | $543.87 Million USD |
| Reuters | $543.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more